Boise State University

ScholarWorks
Biomolecular Research Center Publications and
Presentations

Biomolecular Research Center

5-1-2008

Collagen 11a1 is Indirectly Activated by
Lymphocyte Enhancer-Binding Factor 1 (Lef1)
and Negatively Regulates Osteoblast Maturation
Rachel A. Kahler
University of Minnesota

Sorcha M.C. Yingst
Boise State University

Luke H. Hoeppner
University of Minnesota

Eric D. Jensen
University of Minnesota

David Krawczak
University of Minnesota
See next page for additional authors

This is an author-produced, peer-reviewed version of this article. © 2009, Elsevier. Licensed under the Creative Commons AttributionNonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/). The final, definitive version of this
document can be found online at Matrix Biology, doi: 10.1016/j.matbio.2008.01.002

Authors

Rachel A. Kahler, Sorcha M.C. Yingst, Luke H. Hoeppner, Eric D. Jensen, David Krawczak, Julia T. Oxford,
and Jennifer J. Westendorf

This article is available at ScholarWorks: https://scholarworks.boisestate.edu/brc_facpubs/3

This is an author-produced, peer-reviewed version of this article. The final, definitive version of this document can be found online at Matrix
Biology, published by Elsevier. Copyright restrictions may apply. doi: 10.1016/j.matbio.2008.01.002

Collagen 11a1 is Indirectly Activated by Lymphocyte
Enhancer-binding Factor 1 (Lef1) and Negatively Regulates
Osteoblast Maturation
Rachel A. Kahler1, Sorcha M.C. Yingst2, Luke H. Hoeppner1, Eric D. Jensen3, David Krawczak4,
Julia T. Oxford2 and Jennifer J. Westendorf 5

1

Graduate Program in Microbiology, Immunology and Cancer Biology, University of Minnesota, Minneapolis, MN
Department of Biology, Musculoskeletal Research Center, and Biomolecular Research Center, Boise State
University, Boise, ID 83725
3
Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, MN,
4
Cancer Center, University of Minnesota, Minneapolis, MN
5
Departments of Orthopedic Surgery and Biochemistry & Molecular Biology, Mayo Clinic, Rochester, MN 55905
2

Address correspondence to:
Jennifer J. Westendorf, Ph.D.
Mayo Clinic
200 First Street SW
Rochester, MN 55905
Phone: 507-538-5651; Fax: 507-284-5075
Email: westendorf.jennifer@mayo.edu

Keywords: Lef1, Wnt, beta-catenin, collagen 11a1, osteoblasts
Abstract
Alpha 1 (XI) collagen (Col11a1) is essential for normal skeletal development. Mutations in Col11a1 cause Marshall
and Stickler syndromes, characterized by craniofacial abnormalities, nearsightedness and hearing abnormalities.
Despite its link to human diseases, few studies have characterized the factors that control Col11a1 transcription. We
previously identified Col11a1 as a differentially expressed gene in Lef1-suppressed MC3T3 preosteoblasts. Here
we report that Lef1 activates the Col11a1 promoter. This activation is dependent upon the DNA binding domain of
Lef1, but does not require the β-catenin interaction domain, suggesting that it is not responsive to Wnt signals.
Targeted deletion of Col11a1 with an antisense morpholino accelerated osteoblastic differentiation and
mineralization in C2C12 cells, similar to what was observed in Lef1-suppressed MC3T3 cells. Moreover incubation
with a purified Col11a1 N-terminal fragment, V1B, prevented alkaline phosphatase expression in MC3T3 and
C2C12 cells. These results suggest that Lef1 is an activator of the Col11a1 promoter and that Col11a1 suppresses
terminal osteoblast differentiation.
1. Introduction
Extracellular matrix proteins are essential for the normal formation and function of all tissues (Comper, 1996).
Skeletal tissue is composed of mineral and organic components in combination with various cell types (Gokhale et
al., 2001). Collagens comprise a large percentage of the organic extracellular matrix in bone. Type I collagen is the
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major scaffolding protein for mineralized bone and constitutes 90% of the organic matrix (Robey and Boskey,
2003). Other collagens, however, are also important for proper bone formation. Minor collagens, such as types III,
V, VI and XI collagen, control fibril growth, diameter and assembly of major collagens (Gelse et al., 2003; Robey
and Boskey, 2003).
Type XI collagen is a minor fibril-forming collagen. It is a heterotrimer of alpha 1 (XI) collagen (Col11a1), alpha 2
(XI) collagen (Col11a2) and alpha 1 (II) collagen (Col2a1), except in the vitreous of the eye where Col11a2 is
replaced with alpha 1 (V) collagen (Col5a1) (Fichard et al., 1995). Type XI collagen assists in proper type II
collagen fibril formation (Gelse et al., 2003). Col11a1 is mainly expressed in articular cartilage and the vitreous
fluid of the eye (Lui et al., 1995; Yoshioka et al., 1995; Iyama et al., 2001; So et al., 2001). However, Col11a1
expression is detectable in many other human fetal tissues including the bone (Lui et al., 1995). In mice lacking
Col11a1 (Cho mice), chondrocytes fail to fully differentiate causing a chondrodystrophic phenotype. Cho mice also
have enhanced long bone mineralization, thicker trabeculae, and increased bone mass at the diaphysis (Seegmiller et
al., 1971). Observations from the Cho mice suggest that Col11a1 is essential for skeletal morphogenesis because it
controls type II collagen fibrillogenesis, chondrocyte maturation and bone mineralization (Seegmiller et al., 1971; Li
et al., 1995).
Mutations in Col11a1 cause Marshall and type II Stickler syndromes(Griffith et al., 1998; Annunen et al., 1999).
Marshall syndrome is an autosomal dominant inherited disease characterized by short stature, nearsightedness,
hearing loss, flattened facial features, thickened calvarium and intercranial ossifications. Type II Stickler syndrome
patients have similar symptoms but are of near normal height and exhibit no bony overgrowths (Snead and Yates,
1999). Both syndromes occasionally present with cleft palate and patients frequently develop early osteoarthritis
(Olsen, 1995; Snead and Yates, 1999; Rodriguez et al., 2004; Jakkula et al., 2005). Whether Marshall and Stickler
syndromes are variants of the same disease or separate syndromes is controversial, but it is apparent that they are
very similar and many patients display symptoms of both diseases (Winter et al., 1983; Ayme and Preus, 1984;
Stratton et al., 1991; Annunen et al., 1999).
Lef1 is one four nuclear high mobility group (HMG) proteins that mediate gene transcription in response to
canonical Wnt signaling, which is an important regulator of skeletal development and bone homeostasis (reviewed
in (Westendorf et al., 2004)). Lef1 is essential for mesenchymal/epithelial interactions that occur during the
development of tissues such as mammary glands, teeth and whiskers (van Genderen et al., 1994). Lef1 null mice are
smaller than wild type mice and die shortly after birth. A mouse model expressing a mutant form of Lef1 lacking
the HMG domain (Lef1-βgal) displays several skeletal abnormalities, mostly associated with skeletal patterning
(Galceran et al., 2004). Recently, we recently discovered that Lef1 binds to Runx2 through the Lef1 HMG domain
and represses Runx2-induced transcription of the osteocalcin promoter. This repression is further enhanced by
mimicking canonical Wnt signaling with stabilized β-catenin (Kahler and Westendorf, 2003). We previously
showed that in vitro, osteoblasts with reduced Lef1 expression mineralize at an accelerated rate while osteoblasts
over expressing Lef1 do not mineralize (Kahler et al., 2006). These data suggest that Lef1 may have an important
role in normal osteoblast maturation.
While we reported a role for Lef1 in osteoblast maturation, the exact mechanism by which Lef1 affects osteoblast
differentiation is unknown. In this report, we describe a role for Lef1 in the expression of Col11a1. We
demonstrate that Lef1-suppressed preosteoblasts express Col11a1 mRNA at reduced levels compared to control
cells. An antisense morpholino that inhibits Col11a1 translation enhances differentiation of C2C12 cells along the
osteoblast lineage in a manner similar to Lef1-suppression (Kahler et al., 2006). Moreover, incubation with an Nterminal fragment of Col11a1 slows alkaline phosphatase production by pre-osteoblasts. These data suggest that
Lef1 is important for Col11a1 expression and Col11a1, in turn, plays a role in controlling osteoblast differentiation
and mineralization.
2. Results
2.1. Lef1-suppressed cells have reduced Col11a1 expression
To identify genes that were differentially regulated as a result of Lef1 suppression, we subjected RNA samples from
control (Ffl cells) and Lef1-suppressed (L2) MC3T3 cells to gene chip analysis (Kahler et al., 2006). One group of
genes that was consistently and significantly downregulated in Lef1-suppressed osteoblasts was the collagen family.
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The gene chip analyses indicated that collagens 3a1, 5a1, 6a2 and 11a1 were all downregulated 1.5-fold or more at a
significance of p ≤ 0.005 [Fig. 1A and (Kahler et al., 2006)]. Quantitative real time PCR confirmed that each of
these genes were downregulated in Lef1-suppressed cells compared to control cells (Fig. 1A). Col11a1 expression
was reduced between 3.5- and 7-fold (Fig. 1A and (Kahler et al., 2006)).
To verify that Col11a1 protein levels were concomitantly decreased in Lef1-suppressed cells, we treated control
(Ffl) or Lef1-suppressed (L2) MC3T3 cells with osteogenic medium for 14 days. Protein extracts from both the
conditioned media and extracellular matrices were subjected to immunoblot analysis. Collagen 11a1 was detectable
in the conditioned medium of the control cells but not the Lef1-suppressed cells or in the extracellular matrices of
either cell line (Fig. 1B and data not shown). Blotting with anti-decorin antibody shows that both samples contained
similar amounts of protein (Fig. 1B). Similar results were obtained with MC3T3 clone 14 cell lines (data not
shown). These data show that Lef1 suppression leads to reduced expression of Col11a1 mRNA and protein. In
these conditions, it also appears that Col11a1 is mostly secreted into the medium and not integrated into the
extracellular matrix. Decorin was readily detectable in the extracellular matrix (data not shown).
2.2. Lef1 activates the Col11a1 promoter
Because Col11a1 was so strongly downregulated in Lef1-suppressed cells, we asked if Lef1 could activate the
collagen 11a1 promoter. We used a collagen 11a1 promoter reporter, pCol11a1(-1454)-luc, containing 1454
upstream of the transcriptional start site and the first exon of human Col11a1 (Fig. 2A) (Yoshioka et al., 1995).
When transiently transfected into C2C12 cells, Lef1 activated the reporters 4-8-fold and in a concentrationdependent manner (Fig. 2B & C), but had no effect on the empty luciferase reporter plasmid, pGL3. Lef1 also
activated the Col11a1 promoter in other cell lines, including MC3T3, NIH3T3 and ROS cells, albeit at lower levels
(1.5 to 6 fold) (data not shown).
2.3. The Lef1 HMG domain is necessary for activation of the Col11a1 promoter
We next sought to determine whether Lef1 DNA binding activity is necessary for activation of the Col11a1
promoter. To test this, we used a Lef1 construct that lacks the HMG domain (Lef1∆HMG), which is necessary for
DNA binding (Fig. 3A). Lef1∆HMG was unable to activate the Col11a1 reporter (Fig. 3B). These data suggest that
Lef1 requires the HMG domain to activate the Col11a1 promoter, either through its DNA binding domain or
through interaction with other proteins.
2.4. Lef1’s β-catenin binding domain is not required for activation of the Col11a1 promoter
In many systems, Lef1 interaction with β-catenin is necessary for Lef1-mediated activation of target genes
(reviewed in (Behrens et al., 1996; Clevers and van de Wetering, 1997). Lef1 lacking the β-catenin binding domain
is still able to bind DNA and thus could compete with β-catenin-responsive Lef1 isoforms for DNA binding sites
(reviewed in (Waterman, 2004)). To determine whether Lef1-mediated activation of the Col11a1 promoter was
dependent upon interaction with β-catenin, we utilized an N-terminally truncated Lef1 mutant protein lacking the
high affinity β-catenin binding domain (Fig. 4A). This construct, Lef1∆β-cat, activated the Col11a1 promoter in a
dose dependent manner (Fig. 4B) and enhanced activation by full length Lef1 in an additive manner (Fig. 4B).
These data indicate that Lef1 does not require interaction with β-catenin to activate the Col11a1 promoter.
Furthermore, Lef1∆β-catenin does not behave as a competitive transcription factor at the Col11a1 promoter,
suggesting that expression of Col11a1 by Lef1 may be Wnt-independent.
2.5. Reduced Col11a1 expression enhances osteoblastic differentiation of C2C12 cells
When induced to differentiate, Lef1-suppressed MC3T3 preosteoblasts express osteoblast markers and mineralize
earlier than control cells (Kahler et al., 2006). To determine the role of Col11a1 in osteoblast maturation, C2C12
cells were cultured with BMP-2 in the presence or absence of an antisense morpholino specifically designed to
downregulate the protein expression of Col11a1 by sterically blocking the translation of the Col11a1 mRNA.
Control C2C12 cells that were either untransfected or transfected with a non-specific morpholino expressed Col11a1
protein at the time of induction and Col11a1 levels increased until 24 hours after the addition of BMP-2 (Fig. 5,
panels A, B, D, E, G, H). By 48 hours following the addition of BMP-2, Col11a1 expression was nearly
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undetectable (Fig. 5, panel J and K). C2C12 cells transfected with the Col11a1 antisense morpholino expressed
considerably less Col11a1 protein at any time point, illustrating the effectiveness of the antisense morpholino (Fig.
5, Panels C, F, I, L). These data suggest that Col11a1 is expressed early in osteoblastic differentiation but that its
expression is quickly downregulated as osteoblasts mature.
To determine the effect of the Col11a1 morpholino on osteoblastic differentiation, we cultured C2C12 cells in
osteogenic medium containing BMP-2 in the presence or absence of the Col11a1 antisense or the control
morpholino and then stained the cells for alkaline phosphatase activity and mineralization. C2C12 cells that were
transfected with the Col11a1 antisense morpholino exhibited increased alkaline phosphatase activity and von Kossa
staining as compared to C2C12 cells that were untreated or transfected with a control morpholino (Fig. 6). These
data indicate that Col11a1 I a negative regulator of osteoblast differentiation.
2.6. An N-terminal fragment of Col11a1, V1B, blocks alkaline phosphatase production by pre-osteoblasts.
We next sought to confirm the role of Col11a1 as a negative regulator of osteoblast maturation by determining the
consequence of increased Col11a1 protein during osteoblast differentiation. To test this, we cultured C2C12 cells in
osteogenic medium containing BMP-2 in the presence of Col11a1 N-terminal fragments V0 or V1B. The Nterminal fragments V0 and V1B represent variations of the domain of Col11a1 that remains associated with the
surface of collagen fibril for an extended period of time. V0 and V1B are the two most prevalent isoforms
implicated in mineralization of the bone collar in long bone development (Davies et al 1998, Morris et al. 2000). In
addition, the N-terminal fragments are proteolytically released from the surface of collagen fibrils slowly but at
isoform-specific rates of processing (Thom et al. 1991, Medeck et al. 2003). As compared to control cells, C2C12
cells treated with V1B had a 60% decrease in alkaline phosphatase production after two days and 28% reduction
after five days (Fig. 7A), but only the former level reached statistical significance (p<0.5). Similarly, MC3T3 cells
treated with Col11a1 V1B fragment exhibited reduced expression of alkaline phosphatase compared to control
MC3T3 cells at days three and nine of differentiation in osteogenic medium (Fig. 7B), but only the 73% reduction at
day three was statistically significant (p<0.001). Fragment V0 also suppressed alkaline phosphates production in
MC3T3 cells albeit to a lesser (39%) but significant level (p<0.01) at day three. V0 did not affect alkaline
phosphatase production by C2C12 cells. These data support the role of Col11a1 as a negative regulator of osteoblast
maturation in an isoform-specific manner. V1B has been found specifically expressed in the cartilage immediately
underlying the perichondrium, yet excluded from the developing articular surface, further supporting the hypothesis
of distinct functions for the different isoforms.
3. Discussion
Collagen 11a1 is mutated in Marshall and Stickler syndromes (Snead et al., 1996; Griffith et al., 1998; Meisler et al.,
1998; Annunen et al., 1999; Martin et al., 1999; Snead and Yates, 1999). Patients with Marshall syndrome exhibit
short stature and bony overgrowths on the skull (Stratton et al., 1991; Meisler et al., 1998), suggesting a role for
Col11a1 in controlling bone mineralization. Further evidence for this conclusion is apparent in the Cho mice, which
exhibit excess mineralization in the long bones (Seegmiller et al., 1971; Li et al., 1995). Sequence variations in the
Col11a1 gene are also associated with osteoarthritis, early-onset osteoarthritis, degenerative lumbar spinal stenosis
and cleft palate (Melkoniemi et al., 2003; Noponen-Hietala et al., 2003; Rodriguez et al., 2004; Jakkula et al., 2005).
Its association with a variety of common diseases makes Col11a1 an important target for musculoskeletal disease
research.
This report highlights a role for Lef1 in regulating Col11a1 expression. Reduced Lef1 expression correlates with
decreased expression of Col11a1 mRNA and protein [Fig. 1 and (Kahler et al., 2006)]. Transient transfection assays
indicated that Lef1 activates the Col11a1 promoter in a concentration-dependent manner (Fig. 2). These data are
consistent with a study which found a correlation between Col11a1 expression in colorectal carcinoma and an
activated β-catenin-Lef1/Tcf pathway (Fischer et al., 2001). Analysis of the Col11a1 promoter identified at least six
potential Lef1 binding sites, but only two were found to bind Lef1 in vitro (data not shown). Mutating these sites
individually or all together did not eliminate the activation of the reporter by Lef1. These data suggest that Lef1
activates the Col11a1 promoter indirectly, perhaps through the HMG domain, which is essential for Lef-1 mediated
activation.
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Despite the seriousness of Marshall and Stickler syndromes and the implications of Col11a1 expression in
osteoarthritis and other common disorders, there are only a handful of reports on the transcriptional control of the
Col11a1 gene. The initial studies defining the Col11a1 promoter identified the minimal promoter containing cell
type specificity as the fragment from -199 to +269 (Yoshioka et al., 1995). However, the most active promoter
fragment in this study contained nucleotides -541 to +269. We found that this fragment remains responsive to Lef1
(data not shown). Yoshioka, et al. identified nine DNase I protected footprints in the region of the promoter
containing bases -541 to + 269, most of which were identified as probable binding sites for ubiquitously expressed
proteins NF-κB, CF1, AP2, AP3 and Sp1. (Yoshioka et al., 1995). One footprint was determined to be a binding
site for a zinc-finger protein that was termed FP9C (Kinoshita et al., 1997). The only reported zinc-finger protein to
interact with Tcf/Lef1 is Kaiso, which competes with β-catenin for binding to Tcf-3 resulting in transcriptional
repression of the Samois gene in X. laevis (Park et al., 2005). This is unlikely to be the factor through which Lef1
activates the Col11a1 promoter for several reasons. First, the Kaiso binding sequence does not match that of the
unidentified zinc-finger protein FP9C. Second, Kaiso competes with β-catenin binding to Tcf/Lef1 and the βcatenin binding domain is not necessary for activation of the Col11a1 promoter (Fig. 2 and 3). Finally, Kaiso is
reported to be a repressor of transcription so interaction between Lef1 and Kaiso is unlikely to result in
transcriptional activation (Kim et al., 2004; Park et al., 2005; Spring et al., 2005).
A second transcription factor reported to interact with the Col11a1 promoter is CBF/NF-Y (Matsuo et al., 2003).
This transcription factor binds to the Col11a1 promoter within the -147 to -121 region the and activates transcription
of promoter (Matsuo et al., 2003). At this time, there is no evidence to suggest that Lef1 could be activating the
Col11a1 promoter indirectly through CBF/NF-Y. We found that Lef1 did not cooperate with NF-Y (data not
shown). We also did not detect any changes in CBF/NF-Y expression in the gene chip experiment performed with
Lef1-suppressed cells, suggesting that the activity of Lef1 on the Col11a1 promoter is not through changes in
CBF/NF-Y expression (data not shown). Further studies will have to be performed to determine the nature of Lef1’s
interaction with the Col11a1 promoter whether it is through the above-mentioned mechanisms or through some
other undetermined mechanism.
Though the importance of Col11a1 has been established through the detrimental effects of the loss of normal
Col11a1 expression in Marshall and Stickler syndromes, the exact role Col11a1 plays in bone formation has not yet
been identified. This report shows a link between Lef1 and Col11a1 both in the ability of Lef1 to activate the
Col11a1 promoter and the osteoblastic phenotype resulting from reduced expression of both Lef1 and Col11a1. We
previously reported that using RNAi to reduce Lef1 expression leads to accelerated osteoblast maturation
characterized by early expression of osteoblast markers and enhanced matrix mineralization (Kahler et al., 2006).
Lef1-suppressed cells have reduced Col11a1 expression (Fig. 1). When we used an antisense morpholinos to mimic
the reduced Col11a1 expression seen in Lef1-suppressed cells, we observed that alkaline phosphatase expression
and mineralization were enhanced (Fig. 6). In accordance, exposure to a Col 11a1 N-terminal fragment delayed
early osteoblast maturation as measured by alkaline phosphatase expression. These data suggest that one of the
main mechanisms for the enhanced differentiation we observed as a result of reducing Lef1 levels is the reduction of
Col11a1. They also suggest that Col11a1 is important for controlling the rate of osteoblast mineralization. The V0
and V1B containing isoforms of Col11a1 constitute 70% to 80% of the total Col11a1 transcripts in growth plate
cartilage, including the region undergoing mineralization to form the bone collar between the cartilage and the
perichondrium. V1B Col11a1 shows a restricted distribution in the cartilage of the developing long bones. Before
primary ossification, V1B is expressed only in the diaphysis, primarily adjacent to the perichondrium, a location
consistent with a role in the inhibition of osteoblast differentiation and mineralization. This unique localization of
V1B may indicate that it is involved in the signaling between the cells of the perichondrium, associated
chondrocytes and differentiating osteoblasts.
The main function of type XI collagen is to control fibrillogenesis of type II collagen (Gelse et al., 2003). However,
this function requires the integration of type XI collagen into matrix containing type II collagen (Gelse et al., 2003).
Furthermore, the expression of each of the individual type XI collagen genes is varied from tissue to tissue,
suggesting that they do not form heterotrimers in all tissues and hence the function of each type XI collagen
molecule might be tissue specific (Lui et al., 1995). When we examined the expression of Col11a1 upon induction
of osteoblastic differentiation, we observed very early expression of Col11a1 with nearly a complete loss of
expression by 48 hours (Fig. 5). It is possible that Col11a1 is incorporated into the matrix but cannot be detected by
immunofluorescence. However, we were unable to detect Col11a1 protein in the matrix of differentiating
osteoblasts by immunoblotting, a method that easily detected Col11a1 in the supernatant (Fig. 1). The absence of
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Col11a1 in the matrix suggests that the role of Col11a1 in osteoblast differentiation is separate from its role in
controlling fibrillogenesis in other tissues. The mechanism by which the reduction of Col11a1 expression induces
enhanced mineralization and alkaline phosphatase remains to be determined. However, its presence outside of the
matrix might suggest a role in regulating the availability of growth factors or as a signaling molecule itself
(reviewed in (Tran et al., 2004; Bi et al., 2005; Bix and Iozzo, 2005; Iozzo, 2005; Tran et al., 2005)).
4. Experimental Procedures
4.1. Plasmids
The luciferase reporter construct (pCol11a1(-1454)-luc was kindly provided by Dr. Francesco Ramirez (Kinoshita et
al., 1997; Matsuo et al., 2003). Dr. Liliana Attisano provided pCMV5B-Lef1-HA and pCMV5B-Lef1∆HMG-HA.
Dr. Randall Moon provided pCMV5-Lef1∆β-catenin.
4.2. Cell Culture and Differentiation
MC3T3 Ffl and MC3T3 L2 cells were described previously (Kahler et al., 2006). MC3T3 cells were maintained in
minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino
acids, 200 mM L-glutamine, 50 units/ml penicillin and 50 µg/ml streptomycin. To induce differentiation, confluent
MC3T3-E1 were transferred to differentiation medium (α-MEM supplemented with 10% FBS, 50 units/ml
penicillin, 50 µg/ml streptomycin, 50 µg/ml ascorbic acid and 10 mM β-glycerolphosphate), which was replaced
every three days.
C2C12 cells were maintained at 1.5 x 105 cells per 75 cm2 in Dulbecco’s modified Eagle’s medium (DMEM)
(Gibco) containing 10% FBS (Gibco), 100U/ml penicillin and 100 µg/ml streptomycin, at 37°C in a humidified
atmosphere, 5% CO2. To induce differentiation along the osteoblastic lineage, C2C12 cells were plated at 2 x 104
cells/cm2 and the medium was replaced with DMEM containing 5% FBS, 100U/ml penicillin, 100 µg/ml
streptomycin and 300 ng/ml of BMP-2 for the indicated lengths of time.
Twelve micromolar of either Col11a1 antisense (5’- ACCTGGACCAGGGCTCCATCACCAA -3’) or standard
control morpholino, (5’-CCTCTTACCTCAGTTACAATTTATA-3’) (Gene Tools) and 6 µM of Endo-Porter (Gene
Tools) were added to C2C12 cells at 2 x 104 cells/cm2. Cells were incubated for 24 hours in medium containing 5%
FBS, 100 U/ml penicillin and 100 µg/ml streptomycin prior to inducing osteoblastic differentiation as described
above.
One microgram of either Col11a1 N-terminal fragment V0 or V1B purified protein was added to C2C12 cells and
MC3T3 cells cultured in osteogenic medium as described above at a density of 1.5 x 105 cells per well of a 12-well
plate. Col11a1 V0 or V1B protein was added to the cells every 3 days over the course of the differentiation when
the medium was replaced.
4.3. Collagen Fragment Synthesis
V0 and V1B sequences were amplified, cloned and expressed as described previously (Gregory et al 2000).
Recombinant proteins were purified, refolded and characterized as previously described (Warner et al. 2007).
4.4. Alkaline Phosphatase and von Kossa Staining
C2C12 cells were plated at 2 x 104 cells/cm2 on tissue culture-treated glass slides (Nunc) in the presence or absence
of the collagen 11a1 antisense or control morpholino for 14 days with 300 ng/ml of BMP-2 (R&D Systems). C2C12
cells were then fixed for 5 minutes in cold methanol and incubated for 45 minutes in 0.1 mg/ml of naphthol AS-MX
phosphate, 0.4% N, N-Dimethylformamide, 0.2M Tris-HCl pH 8.3 and 0.6mg/ml of Red Violet LB salt. The slides
were then washed in distilled water four times and stained with 2.5% silver nitrate for 30 minutes, followed by 4
washes in distilled water.
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4.5. Cell Transfection and Luciferase Assays
Prior to transfection, C2C12 cells were seeded at a density of 4 x 104 cells/well into 12-well plates and allowed to
adhere overnight. C2C12 cells were transiently transfected with pGL3 or pGL3-Col11a1-luc (200 ng/well), pRLnull (50 ng/well), and pCMV5B-Lef1-HA, pCMV5B-Lef1∆HMG-HA or pCMV5-Lef1∆β-catenin as indicated
using LipofectAMINE (Invitrogen) as directed by the manufacturer. Transcription of luciferase reporter constructs
was measured using the Dual-Luciferase Reporter Assay System kit (Promega) according to the manufacturer’s
instructions 24 hours after transfection.
4.6. Reverse Transcriptase Polymerase Chain Reaction
RT-PCR was performed by reverse transcribing 1 µg RNA using the Invitrogen Superscript First-Strand Synthesis
System for RT-PCR. Targets were amplified from the cDNA, 1 µl of a 1:10 dilution, using the sequence-specific
primers: Lef1 forward 5’-TCACTGTCAGGCGACACTTC-3’, Lef1 reverse 5’-TGAGGCTTCACGTGCATTAG3’, Col3a1 forward 5’-GTCCACGAGGTGACAAAGGT-3’, Col3a1 reverse 5’-CATCTTTTCCAGGAGGTCCA3’, Col5a1 forward 5’-TGCCCTCTGACTGCCTCTAT-3’, Col5a1 reverse 5’-CACATTGCAGCCTGAAAGAA-3’,
Col6a2 forward 5’-CTTCCCCTACCCCAAGTCTC-3’, Col6a2 reverse 5’-TGATATGGGGCTCTCAGGTC-3’,
Col11a1 forward 5’-CTGGTCATCCTGGGAAAGAA-3’, Col11a1 reverse 5’-TTGAATCCTGGAAAGCCATC-3’,
Actin forward 5’-AAGGAAGGCTGGAAAAGAGC-3’, Actin reverse 5’-GCTACAGCTTCACCACCACA-3’,
Alkaline phosphatase forward 5’-TGTTGACAAGGCAGACAAGC-3’, Alkaline phosphatase reverse 5’CAGGACCGTTGCCGTATAGT-3’. Standard RT-PCRs were performed in a Bio Rad iCycler. All quantitative
PCRs were done in a Roche Light Cycler. Amplification of targets was performed on cDNA using the SYBR Green
Taq ReadyMix, Capillary Formulation (Sigma).
4.7. Extracellular Matrix Preparation
Media were collected from 14-day differentiation cultures and the remaining cells were washed once with 0.5 M
acetic acid. The washes were pooled with the conditioned media before equal volumes of 4 M NaCl in 0.5 M acetic
acid were added. Proteins were precipitated by incubating this mixture for 48 hours at 4° C. To collect the
extracellular matrix proteins, the washed cells were treated overnight with 1 mg/ml pepsin in 0.5 M acetic acid at 4°
C. The supernatants were collected and proteins precipitated as described above. All protein precipitates were
collected by centrifugation for 1 hour at 26,000 x g, resuspended in 0.5 M acetic acid and dialyzed against 0.5 M
acetic acid to remove the salts. The samples were then lyophilized and resuspended in 0.5 M acetic acid.
4.8. Immunoblotting
Protein was quantitated using the Bio-Rad DC Protein Assay kit. Protein aliquots were mixed with non-reducing
protein sample dye and resolved by SDS 7% PAGE. Proteins were transferred to PVDF membranes for
immunoblotting with a rabbit polyclonal antibody recognizing the C-telopeptide domain of collagen 11a1 (20545)
(Li et al., 1995; Davies et al., 1998) or mouse monoclonal anti-decorin antibody (Scott et al., 1993). Col11a1 and
decorin antibodies were diluted 1:1000 and 1:40, respectively, in TBST (TBS, 0.4% tween-20) with 3% BSA. Dr.
Paul G. Scott graciously provided the anti-decorin antibody.
4.9. Immunofluorescence and Microscopy
C2C12 cells were plated as described above on glass slides in the presence or absence of Col11a1 antisense or
control morpholinos. All treatment groups received 300 ng/ml of BMP-2 following 24 hours incubation with the
indicated morpholino. The cells were fixed for 5 minutes in cold methanol at the indicated time points ranging from
0 hours to 48 hours following treatment with BMP-2. The slides were then rinsed in TBS and permeablized in TBS0.5% Triton X-100 (TX) for 10 minutes. The slides were washed 3x 5 minutes in TBS-0.1% TX, followed by
blocking with 2% BSA in TBS-0.1% TX for 10 minutes. Anti-collagen 11a1 antibody was added to the slide at a
dilution of 1:100 in 2% BSA, TBS-0.1% TX for 1.5 hours in a humidified chamber at 37°C. The cells were
subsequently washed 5x 5minutes in TBS-0.1% TX. Following the last wash, the secondary antibody, a Rhodamine
(TRITC)-conjugated AffiniPure Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Laboratories) diluted 1:100 in
TBS-0.1% TX was added and incubated for 1 hour in a humidified chamber at 37°C. The slides were then washed
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3x 5 minutes in TBS-0.1% TX and incubated in 3.0 µg/ml of DAPI for 10 minutes (Molecular Probes). The slides
were again washed 3x 5 minutes in TBS-0.1% TX, rinsed once in TBS, drained, mounted with Vectashield
according to the manufacturer’s protocol (Vector Laboratories) and sealed.
For microscopic observation and photomicrography of the fluorescently labeled cells, an Olympus BX60
fluorescence microscope equipped with a PM-10AD system for photomicrography was used. The fluorescent
molecules were excited with a 100 W mercury lamp. TRITC-labeled molecules were detected with a filter set
having a 510-560 nm wavelength bandpass, a 565 nm dichroic beamsplitter and a 575 to 645 nm emission filter
(scale 10 nm).
For microscopic observation and photomicrography of the general morphology and of alkaline phosphatase and Von
Kossa staining of the cells, a Nikon Inverted Microscope Eclipse TS100-F equipped with a Spot Insight Color
digital camera and software was used (Nikon Instruments Inc.). The cells were detected with a 40x objective using
Hoffman Modulation Contrast (HMC) microscopy (scale 10nm).
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Figure Legends
Figure 1. Col11a1 expression is reduced in Lef1-deficient cells. A. The relative change in expression of
collagen 11a1 in Lef1-suppressed MC3T3 cells (L2) as compared to control cells expressing a short hairpin RNA
against firefly luciferase (Ffl). Black bars depict fold reduction of expression ± SD as measured by gene chip
analysis with a p-value ≤ 0.05. Grey bars depict fold reduction of expression ± SD as measured by quantitative RTPCR. B. Immunoblot analysis of protein precipitated from L2 or Ffl cell-conditioned media. The upper panel is
blotted with α-collagen 11a1 antibody. The lower panel is blotted with α-decorin antibody as a protein loading
control.
Figure 2. Lef1 activates the Col11a1 promoter. A. This schematic depicts the Col11a1 promoter used in this
study. pCol11a1(-1454)-luc encompasses bases -1454 to +269. B. C2C12 cells were transfected with pGL3 or
pGL3-Col11a1(-1454)-luc, pRL-null and 200 ng of either pcDNA (-) or pCMV5B-Lef1-HA. Transcriptional
activation is shown as fold luciferase activity over control ± SEM and corrected for transfection efficiency relative
to renilla expression. C. C2C12 cells were transfected with pGL3-Col11a1(-1454)-luc, pRL-null and the indicated
concentrations of pCMV5B-Lef1-HA. Data were analyzed as in B.
Figure 3. The HMG domain of Lef1 is required for activation of Col11a1 promoter. A. This schematic
depicts the Lef1 and Lef1∆HMG expression constructs used in these experiments. β-cat BD, β-catenin binding
domain; TLE BD, TLE binding domain; HMG,high mobility group domain. B. C2C12 cells were transfected with
pCol11a1(-1454)-luc, pRL-null and 200 ng of either pcDNA3 (-), pCMV5-Lef1-HA (Lef1), or pCMV5Lef1∆HMG-HA (∆HMG) as indicated. Transcription is measured as fold luciferase activity over control ± SEM.
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Figure 4. Interaction with β-catenin is not required for Lef1-mediated activation of the Col11a1 promoter.
A. This diagram depicts Lef1 and Lef1∆β-cat. Abbreviations are listed in Fig. 5A. B. C2C12 cells were
transfected with pCol11(-1454)-luc, pRL-null, 200 ng pCMV5B-Lef1-HA and either 200 ng pcDNA3 (-) or the
indicated amount of Lef1∆β-cat.
Figure 5. Col11a1 expression is inhibited by Col11a1 antisense morpholinos. A-C. C2C12 cells were treated
with either no (A), control (B) or Col11a1 antisense morpholinos (C) and immunofluorescently stained with an antiCol11a1 primary antibody and a TRITC-labeled secondary antibody. D-L. C2C12 cells were treated with the
indicated morpholinos and induced to differentiate into the osteoblastic lineage by treatment with BMP-2 for the
indicated length of time, followed by immunofluorescent staining as above.
Figure 6. A Col11a1 antisense morpholinos induces increased expression of osteoblast markers. C2C12 cells
were treated either with no (A), control (B) or Col11a1 antisense morpholinos (C) and stained for alkaline
phosphatase activity (red) and mineralization (von Kossa staining, black) after 14 days treatment with BMP-2.
Figure 7: Alkaline phosphatase expression is inhibited during osteoblast differentiation by an N-terminal
Col11a1 fragment, V1B. C2C12 cells were differentiated in osteogenic medium supplemented with BMP2 for five
days (A) and MC3T3-E1 cells were differentiated in osteogenic medium for nine days (B) in the presence of vehicle
alone, Col11a1 V0 fragment, or Col11a1 V1B fragment. RNA was collected at the indicated time points and
quantitative PCR was performed using alkaline phosphatase and actin specific primers. Alkaline phosphatase values
were normalized to actin.
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